Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Correlation Between Screening Guidelines and Decline in HPV-Related Cervical Cancer May Useful for Other Cancers

May 19, 2021
By Audrey Sternberg
Article
Conference|ASCO Annual Meeting

For the past 17 years, HPV-related cervical cancer has been declining, however, other tumors related to the virus continue to remain steady.

Human papillomavirus (HPV)–related cervical cancers have shown a decline, based on evidence from a population-based study. Why may help to potentially clear guidence around screening for other HPV tumor types.1,2

On the other hand, the incidence of other HPV-related cancers without clear screening guidelines are on the rise in both men and women.

“In young women, cervical carcinoma is decreasing consistently with screening, and possibly vaccination, at the population level,” lead author Cheng-I Liao, MD, of Kaohsiung Veterans General Hospital in Kaohsiung, Taiwan, said during a presentation of the data during a media briefing leading up to the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

HPV is associated with more than 90% of cervical and anal cancers and 60% to 75% of oropharyngeal, vulvar, vaginal, and penile tumors.3 The purpose of the study was to assess trends in the incidence of HPV-associated cancer using the United States Cancer Statistics Database from 2001 to 2017. 

In the 17-year timeframe, there were 657,317 cases of cancer, 393,298 (60%) of which were in women. The most commonly occurring cancer in female patients was cervical carcinoma (52%). In men (n = 264,019), the most common malignancy was oropharyngeal squamous cell carcinoma (SCC; 80%), which represents a 5-fold higher incidence compared with women.

Over the study period, cervical cancer incidence decreased by 1.03% per year (P <.05), but this rate was significantly higher in patients aged 20 to 24 years who saw a much greater decrease in disease incidence, at 4.63% per years. Similar effects were seen in women over the age of 65, who saw a greater than 2% incidence decline over the study period (P <.05). The investigators said this is likely due to the effects of HPV vaccination and screening.

However, other HPV-related cancers without standardized screening guidelines saw increases over the study period, with a 2.71% incidence rise per year in men and a 0.77% increase in women. Other HPV-associated cancers included anal and rectal SCC, oropharyngeal SCC, penile cancer, vulvar SCC, and vaginal SCC.

In women over the age of 50, the annual percentage change in the incidence of anal and rectal SCC was 3.55% (P <.001). When compared with the 1.53% decline in the incidence of cervical cancer in the same patient population (P <.001), trends suggest that HPV-related anal and rectal SCC will surpass its incidence in the coming decade, and likely in the next 5 years.

“The decrease in cervical cancer is welcome news and may reflect intensive efforts to screen and vaccinate patients at risk,” ASCO President Lori J. Pierce, MD, FASTRO, FASCO, said in a press release. “Clearly, this study shows that we still have a great deal of work to do in order to reverse the increasing incidence rates of other HPV-related cancers.”

The investigators plan to gather information from other databases about the rate of HPV testing and vaccination. Additional research will be necessary to tackle a lack of disease screening and vaccination recommendations for HPV-associated cancers other than cervical.

References
1. HPV associated cancers in the US over the last 17 years – has screening or vaccination made any difference? Presented at: 2021 ASCO Annual Meeting Virtual Embargoed Presscast; May 19, 2021; Virtual.
2. With Strong Screening and Vaccination Guidelines, Cervical Cancer Rates Drop; Other HPV-Related Cancers Are on the Rise. News release. American Society of Clinical Oncology. May 19, 2021. Accessed May 19, 2021. https://bit.ly/3ylfjJ1
3. Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086. doi:10.1093/jnci/djv086

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

Subgroup Data Sustain Cadonilimab Survival Benefit in Cervical Cancer

Subgroup Data Sustain Cadonilimab Survival Benefit in Cervical Cancer

Jason M. Broderick
June 18th 2025
Article

The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.

Read More


Advancing the Treatment of Cervical and Endometrial Cancers

Advancing the Treatment of Cervical and Endometrial Cancers

June 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Listen


Ipi/Nivo Combo Extends Survival in Advanced Kidney Cancer

Ipi/Nivo Combo Extends Survival in Advanced Kidney Cancer

Hannah Clarke
June 13th 2025
Article

Read More


Precision Medicine Guiding Ovarian Cancer Treatment

Precision Medicine Guiding Ovarian Cancer Treatment

July 15th 2020
Podcast

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Listen


CREST Trial: Sasanlimab/BCG Improves NMIBC Outcomes

CREST Trial: Sasanlimab/BCG Improves NMIBC Outcomes

Benjamin Saylor
June 11th 2025
Article

Combining sasanlimab with BCG significantly enhances event-free survival in high-risk non-muscle invasive bladder cancer, especially in CIS patients.

Read More


FDA Grants Fast Track Status to PHST001 in Ovarian Cancer

FDA Grants Fast Track Status to PHST001 in Ovarian Cancer

Jordyn Sava
June 11th 2025
Article

The FDA granted fast track designation to PHST001 for the treatment of advanced ovarian cancer.

Read More

Related Content

Subgroup Data Sustain Cadonilimab Survival Benefit in Cervical Cancer

Subgroup Data Sustain Cadonilimab Survival Benefit in Cervical Cancer

Jason M. Broderick
June 18th 2025
Article

The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.

Read More


Advancing the Treatment of Cervical and Endometrial Cancers

Advancing the Treatment of Cervical and Endometrial Cancers

June 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Listen


Ipi/Nivo Combo Extends Survival in Advanced Kidney Cancer

Ipi/Nivo Combo Extends Survival in Advanced Kidney Cancer

Hannah Clarke
June 13th 2025
Article

Read More


Precision Medicine Guiding Ovarian Cancer Treatment

Precision Medicine Guiding Ovarian Cancer Treatment

July 15th 2020
Podcast

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Listen


CREST Trial: Sasanlimab/BCG Improves NMIBC Outcomes

CREST Trial: Sasanlimab/BCG Improves NMIBC Outcomes

Benjamin Saylor
June 11th 2025
Article

Combining sasanlimab with BCG significantly enhances event-free survival in high-risk non-muscle invasive bladder cancer, especially in CIS patients.

Read More


FDA Grants Fast Track Status to PHST001 in Ovarian Cancer

FDA Grants Fast Track Status to PHST001 in Ovarian Cancer

Jordyn Sava
June 11th 2025
Article

The FDA granted fast track designation to PHST001 for the treatment of advanced ovarian cancer.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.